

CLINICAL CANCER RESEARCH

TABLE OF CONTENTS

HIGHLIGHTS

5053 Selected Articles from This Issue

SPECIAL FEATURES

Special Report

5055 **AACR Cancer Progress Report 2020: Turning Science into Lifesaving Care**
Rajarshi Sengupta and Karen Honey

CCR Translations

5056 **Reimagining Vaccines for Prostate Cancer: Back to the Future**
Eugene Shenderov and Emmanuel S. Antonarakis
See related article, p. 5162

5059 **Quest for Ideal Composite Biomarkers for Response to Immunotherapies**
Umang Swami, Roberto H. Nussenzweig, and Neeraj Agarwal
See related article, p. 5120

CCR Drug Updates

5062 **FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis**
Shaily Arora, Sanjeev Balasubramaniam, Wei Zhang, Lijun Zhang, Rajeshwari Sridhara, Dianne Spillman, Jaigi P. Mathai, Bradley Scott, Sarah J. Golding, Michael Coory, Richard Pazdur, and Julia A. Beaver

Reviews

5068 **Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy**
Jose Carlos Benitez, Jordi Remon, and Benjamin Besse

5078 **Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade**
César Serrano and Suzanne George

CLINICAL TRIAL BRIEF REPORT

5086 **Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B**
Matteo S. Carlino, Alexander M. Menzies, Victoria Atkinson, Jonathan S. Cebon, Michael B. Jameson, Bernard M. Fitzharris, Catriona M. McNeil, Andrew G. Hill, Antoni Ribas, Michael B. Atkins, John A. Thompson, Wen-Jen Hwu, F. Stephen Hodi, Alexander D. Guminski, Richard Kefford, Haiyan Wu, Nageatte Ibrahim, Blanca Homet Moreno, and Georgina V. Long

CLINICAL TRIALS: TARGETED THERAPY

5092 **A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer**
Michael J. Pishvaian, Hongkun Wang, Aiwu Ruth He, Jimmy J. Hwang, Brandon G. Smaglo, Sunnie S. Kim, Benjamin A. Weinberg, Louis M. Weiner, John L. Marshall, and Jonathan R. Brody

5102 **A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with *BRAF*^{V600E/K}-mutant Solid Tumors**
AC Ryan J. Sullivan, Jeffrey Weber, Sapna Patel, Reinhard Dummer, Matteo S. Carlino, Daniel S.W. Tan, Celeste Lebbé, Salvatore Siena, Elena Elez, Lance Wollenberg, Michael D. Pickard, Victor Sandor, and Paolo A. Ascierto

5113 **A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring *HRAS* Mutations**
Hye Won Lee, Jason K. Sa, Antonio Gualberto, Catherine Scholz, Hyun Hwan Sung, Byong Chang Jeong, Han Yong Choi, Ghee Young Kwon, and Se Hoon Park

TABLE OF CONTENTS

CLINICAL TRIALS: IMMUNOTHERAPY

- 5120** **Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275**
Matthew D. Galsky, Abdel Saci, Peter M. Szabo, G. Celine Han, Gary Grossfeld, Sandra Collette, Arlene Siefker-Radtke, Andrea Necchi, and Padmanee Sharma
See related commentary, p. 5059
- 5129** **A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer**
Annie A. Wu, Katherine M. Bever, Won Jin Ho, Elana J. Fertig, Nan Niu, Lei Zheng, Rose M. Parkinson, Jennifer N. Durham, Beth Onners, Anna K. Ferguson, Cara Wilt, Andrew H. Ko, Andrea Wang-Gillam, Daniel A. Laheru, Robert A. Anders, Elizabeth D. Thompson, Elizabeth A. Sugar, Elizabeth M. Jaffee, and Dung T. Le
- 5140** **Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial**
Ravindra Uppaluri, Katie M. Campbell, Ann Marie Egloff, Paul Zolkind, Zachary L. Skidmore, Brian Nussenbaum, Randal C. Paniello, Jason T. Rich, Ryan Jackson, Patrik Pipkorn, Loren S. Michel, Jessica Ley, Peter Oppelt, Gavin P. Dunn, Erica K. Barnell, Nicholas C. Spies, Tianxiang Lin, Tiantian Li, David T. Mulder, Youstina Hanna, Iulia Cirilan, Trevor J. Pugh, Tenny Mudianto, Rachel Riley, Liye Zhou, Vickie Y. Jo, Matthew D. Stachler, Glenn J. Hanna, Jason Kass, Robert Haddad, Jonathan D. Schoenfeld, Evisa Gjini, Ana Lako, Wade Thorstad, Hiram A. Gay, Mackenzie Daly, Scott J. Rodig, Ian S. Hagemann, Dorina Kallogjeri, Jay F. Piccirillo, Rebecca D. Chernock, Malachi Griffith, Obi L. Griffith, and Douglas R. Adkins
- 5153** **Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study**
Kevin J. Harrington, Anthony Kong, Nicolas Mach, Jason A. Chesney, Beatriz Castelo Fernandez, Danny Rischin, Ezra E.W. Cohen, Hoi-Shen Radcliffe, Burak Gumuscu, Jonathan Cheng, Wendy Snyder, and Lillian L. Siu
- 5162** **Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer**
Christos E. Kyriakopoulos, Jens C. Eickhoff, Anna C. Ferrari, Michael T. Schweizer, Ellen Wargowski, Brian M. Olson, and Douglas G. McNeel
See related commentary, p. 5056

PRECISION MEDICINE AND IMAGING

- 5172** **ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials**
A C Nicholas C. Turner, Claire Swift, Lucy Kilburn, Charlotte Fribbens, Matthew Beaney, Isaac Garcia-Murillas, Aman U. Budzar, John F.R. Robertson, William Gradishar, Martine Piccart, Gaia Schiavon, Judith M. Bliss, Mitch Dowsett, Stephen R.D. Johnston, and Stephen K. Chia
- 5178** **First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer**
Mark P.S. Dunphy, Christina Pressl, Nagavarakishore Pillarsetty, Milan Grkovski, Shanu Modi, Komal Jhaveri, Larry Norton, Bradley J. Beattie, Pat B. Zanzonico, Danuta Zatorska, Tony Taldone, Stefan O. Ochiana, Mohammad M. Uddin, Eva M. Burnazi, Serge K. Lyashchenko, Clifford A. Hudis, Jacqueline Bromberg, Heiko M. Schöder, Josef J. Fox, Hanwen Zhang, Gabriela Chiosis, Jason S. Lewis, and Steven M. Larson
- 5188** **A Serum Protein Classifier Identifying Patients with Advanced Non-Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors**
A C Mirte Muller, Karlijn Hummelink, Daan P. Hurkmans, Anna-Larissa N. Niemeijer, Kim Monkhorst, Joanna Roder, Carlos Oliveira, Heinrich Roder, Joachim G. Aerts, and Egbert F. Smit
- 5198** **A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy**
A C Carine El Sissy, Amos Kirilovsky, Marc Van den Eynde, Ana-Maria Mușină, Maria-Gabriela Anitei, Alfredo Romero, Florence Marliot, Audelaure Junca, Jérôme Doyen, Bernhard Mlecnik, Nacilla Haicheur, Tessa Fredriksen, Christine Lagorce, Anne Jouret-Mourin, Daniel Leonard, Frédéric Bibeau, Soledad Iseas, Enrique L. Roca, Ana M. Cabanne, Carlos A. Vaccaro, Juan P. Santino, Eduardo Huertas, David Tougeron, Carlos Carvalho, Nuno Figueiredo, Rodrigo O. Perez, Angelita Habr-Gama, Viorel Scripcariu, Jean-Pierre Gerard, Jérôme Galon, Guy Zeitoun, and Franck Pages

TRANSLATIONAL CANCER MECHANISMS AND THERAPY

- 5208** **Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma**
Jean-Baptiste Bachet, Hélène Blons, Pascal Hammel, Iman El Hariry, Fabienne Portales, Laurent Mineur, Jean-Philippe Metges, Claire Mulot, Camille Bourreau, Jason Cain, Jérôme Cros, and Pierre Laurent-Puig

TABLE OF CONTENTS


- 5217** **TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Anti-PD-1 Response in Follicular Lymphoma**
Zhi-Zhang Yang, Hyo Jin Kim, Hongyan Wu, Shahrzad Jalali, Xinyi Tang, Jordan E. Krull, Wei Ding, Anne J. Novak, and Stephen M. Ansell
- 5232** **Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma**
Erik Ladomersky, Lijie Zhai, Kristen L. Lauing, April Bell, Jiahui Xu, Masha Kocherginsky, Bin Zhang, Jennifer D. Wu, Joseph R. Podojil, Leonidas C. Plataniias, Aaron Y. Mochizuki, Robert M. Prins, Priya Kumthekar, Jeffrey J. Raizer, Karan Dixit, Rimas V. Lukas, Craig Horbinski, Min Wei, Changyou Zhou, Graham Pawelec, Judith Campisi, Ursula Grohmann, George C. Prendergast, David H. Munn, and Derek A. Wainwright
- 5246** **Low-Dose Hsp90 Inhibitor Selectively Radiosensitizes HNSCC and Pancreatic Xenografts**
Ranjit K. Mehta, Sanjima Pal, Koushik Kondapi, Merna Sitto, Cuyler Dewar, Theresa Devasia, Matthew J. Schipper, Dafydd G. Thomas, Venkatesha Basrur, Manjunath P. Pai, Yoshihiro Morishima, Yoichi Osawa, William B. Pratt, Theodore S. Lawrence, and Mukesh K. Nyati
- 5258** **A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer**
AC Susanne Hipp, Vladimir Voynov, Barbara Drobits-Handl, Craig Giragossian, Francesca Trapani, Andrew E. Nixon, Justin M. Scheer, and Paul J. Adam

AC AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows a multiplex immunofluorescence (MIF) image of a nonresponder HNSCC patient with minimal CD8⁺ T-cell infiltrates in a baseline tumor biopsy. CD8⁺ T cell infiltrates at baseline correlated with neoadjuvant anti-PD1 pathologic response in surgically resectable, advanced HNSCC. For details, see article by Uppaluri et al. on page 5140 of this issue.



Clinical Cancer Research

26 (19)

Clin Cancer Res 2020;26:5053-5268.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/26/19>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/26/19>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.